There are 4 parts to this study for which the primary objectives are to evaluate safety and
tolerability, including dose-limiting toxicities (DLTs), and pharmacokinetics (PK) of
navitoclax when administered alone (Part 1) or when administered in combination with
ruxolitinib (Part 2). In Part 2, participants must have been receiving a stable dose of
ruxolitinib therapy for at least 12 weeks prior to study enrollment. In Part 3, all eligible
participants will receive navitoclax, with the primary objective being to evaluate potential
navitoclax effect on QTc prolongation. In Part 4, effect of navitoclax is evaluated on the
PK, safety, and tolerability of a single dose of celecoxib in participants with
myeloproliferative neoplasm (MPN) or chronic myelomonocytic leukemia (CMML).
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.